Five Prime Therapeutics, Inc. | TalkMarkets

Latest Posts

Why Phase 2 Trials Are Important To Investors (And Why I’m Enrolled In One)

Article By: Marc Lichtenfeld

Tuesday, April 6, 2021 10:39 AM EDT

The biotech sector tends to attract investors who are interested in exciting new medical advances and are drawn to big profits. There are lots of ways to invest in the sector.

In this article: FPRX Also: AMGN, GILD

Read

A Month For The Ages

Article By: Bespoke Investment Group

Monday, November 16, 2020 4:18 PM EDT

Just when you think you’ve seen it all from this market, a month like November comes around.

In this article: FPRX Also: EA, HBI, MOS, OXY, REV, RT, TSCO, ULTA, CPS, NLOK

Read

An Activist Fund Has Been Buying This Biotech

Article By: Scott Matusow

Friday, January 17, 2020 11:00 AM EDT

When a fund files a 13D, it indicates that it intends to be an activist investor. Activist investors often facilitate new business paths, partnerships, and acquisitions.

In this article: FPRX Also: BMY, MRK, ZLAB, XOMA

Read

Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals

Article By: ChinaBio® Today

Saturday, December 23, 2017 5:37 PM EDT

Nanjing Legend Biotech and Janssen Biotech will form a global partnership with Legend for its CAR-T candidate and Crown Bioscience, a CRO with facilities in China, Taiwan, US and Europe, will be acquired for $400 million by JSR Corporation of Japan.

In this article: AVEO, CELG, FPRX, TRXC, BGNE, VTVT, ZLAB

Read